Outcome of ovarian cancer patients was significantly improved with niraparib

Bookmark and Share
Published: 8 Oct 2016
Views: 1599
Dr Mansoor Raza Mirza - Copenhagen University Hospital, Copenhagen, Denmark

Dr Raza Mirza presents, at a press conference at ESMO 2016, the results of the ENGOT-OV16/NOVA trial.

They found that the PARP inhibitor niraparib significantly improved the outcome of platinum-sensitive recurrent ovarian cancer.

The trial met its primary endpoint, with niraparib considerably prolonging progression-free survival compared to placebo.

Read the news story or watch the interview for more.